3 Pharmaceutical Company, Tyres Maker and Pipes and Adhesives Maker Stocks With a Strong Future Roadmap: Ipca Laboratories, CEAT and Astral
- November 12, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Ipca Laboratories, CEAT and Astral: ROE of 11.5% to 14.2% and FY22 to FY26 revenue CAGR of 10.6% to 13.8%. Prices as of 11 Nov 2026.
Quick Answer
The three pharma, tyre and pipe stocks to watch are Ipca Laboratories, CEAT and Astral. Their return on equity ranges from 11.5% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 13.8%. Ipca Laboratories has the highest return on equity at 14.2%, while CEAT has the fastest revenue growth at 13.8% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.
Pharma, tyre and pipe stocks offer a focused view of a sector where demand keeps widening. Ipca Laboratories, CEAT and Astral cover a pharmaceutical company, a tyres maker and a pipes and adhesives maker.
This list covers three pharma, tyre and pipe stocks with complete current figures: Ipca Laboratories, CEAT and Astral. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Tyre and Pipe Stocks?
Pharma, tyre and pipe stocks are listed companies that make medicines and active ingredients for India and global markets, make tyres for two wheelers, cars, trucks and farm vehicles, and make plumbing pipes, fittings and adhesives. Their earnings depend on prescription demand, tyre sales and housing and plumbing demand.
Pharma, Tyre and Pipe Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Ipca Laboratories | 1,938.4 | 46,050 | 33.5 | 36.0 | 14.2 | 0.10 |
| CEAT | 3,549.9 | 12,385 | 24.0 | 19.2 | 11.5 | 0.82 |
| Astral | 1,276 | 38,267 | 66.5 | 36.4 | 13.2 | 0.06 |
On valuation, Ipca Laboratories trades at a P/E below the industry P/E, while CEAT and Astral trade above it, which reflects the growth the market already expects. Readers comparing pharma, tyre and pipe stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Tyre and Pipe Stocks Have a Strong Roadmap in India?
Pharma, tyre and pipe stocks have a strong roadmap in India because steady demand for quality medicines, a rising vehicle base and strong housing construction keep widening the market for these companies.
- Pharma. Doctors prescribe trusted brands widely.
- Tyres. More vehicles on the road need more tyres.
- Pipes and adhesives. New homes need plumbing and bonding products.
Why Ipca Laboratories Features Among These Pharma, Tyre and Pipe Stocks
Among the pharma, tyre and pipe stocks on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.
Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.
In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.
Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.
Why CEAT Features Among These Pharma, Tyre and Pipe Stocks
Among the medicine maker, rubber wheel and plumbing shares on this list, CEAT is an RPG Group tyre maker that supplies two-wheeler, passenger car, commercial vehicle, farm and off-highway tyres to vehicle makers, the replacement market and export customers.
Revenue rose from Rs 9,375 crore in FY22 to Rs 15,718 crore in FY26, a compound annual growth rate of 13.8%. Net profit grew from Rs 182 crore in FY23 to Rs 697 crore in FY26, which works out to a compound annual growth rate of 56.4%.
The company has a return on equity of 11.5%, a debt to equity ratio of 0.82 and a market capitalisation of Rs 12,385 crore. The stock trades at a P/E of 24.0, above the industry P/E of 19.2.
Roadmap: The company is widening its premium and radial tyre range and growing its dealer network, which helps it capture the shift to better tyres. A balanced mix of original equipment and replacement sales supports steady demand.
What to watch: Track replacement demand, raw material costs and growth in the premium two-wheeler and passenger tyre ranges.
Why Astral Features Among These Pharma, Tyre and Pipe Stocks
Among the three companies on this list, Astral is a leading maker of plastic piping systems and building products, with CPVC and PVC pipes, adhesives, sealants and bathware sold through a wide distribution network.
The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P/E of 66.5, above the industry P/E of 36.4.
Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore.
Roadmap: The company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.
What to watch: Watch PVC resin price trends and growth in the adhesives and paints businesses.
Ipca Laboratories vs CEAT vs Astral on Key Financials
The table below sets the three pharma, tyre and pipe stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Ipca Laboratories | 5,896 | 9,821 | 13.6% | 1,191 | 12.1% |
| CEAT | 9,375 | 15,718 | 13.8% | 697 | 4.4% |
| Astral | 4,429 | 6,616 | 10.6% | 535 | 8.1% |
Ipca Laboratories posts the highest return on equity in this group at 14.2%. CEAT combines the largest FY26 revenue at Rs 15,718 crore with the fastest revenue growth, a 13.8% compound annual rate. A useful habit with pharma, tyre and pipe stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pharma, Tyre and Pipe Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, tyre and pipe stocks, the main points are: Long-term medicine maker, rubber wheel and plumbing shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Generic prices can change by market.
- Rubber and carbon black costs. Raw material prices can move margins.
- Housing cycles. Real estate and building demand can vary with rates and sentiment.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, tyre and pipe stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Tyre and Pipe Stocks
Pharma, tyre and pipe stocks reward patient research into demand, execution and financial strength. Ipca Laboratories, CEAT and Astral each have a clear plan to grow. Based on the 11 November 2026 close, Ipca Laboratories trades at Rs 1,938.4, CEAT at Rs 3,549.9 and Astral at Rs 1,276.
Download the Univest iOS App or Univest Android App to track pharma, tyre and pipe stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, tyre and pipe stocks?
Ans. Pharma, tyre and pipe stocks are listed companies that make medicines and active ingredients for India and global markets, make tyres for two wheelers, cars, trucks and farm vehicles, and make plumbing pipes, fittings and adhesives. Their earnings depend on prescription demand, tyre sales and housing and plumbing demand. This list looks at three of them, Ipca Laboratories, CEAT and Astral, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.
Which pharma, tyre and pipe stocks are covered in this list?
Ans. This list covers Ipca Laboratories, CEAT and Astral. Based on the 11 November 2026 close, Ipca Laboratories traded at Rs 1,938.4, CEAT at Rs 3,549.9 and Astral at Rs 1,276. Their return on equity ranges from 11.5% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 13.8%.
Why do pharma, tyre and pipe stocks have a strong future roadmap in India?
Ans. Pharma, tyre and pipe stocks have a strong roadmap in India because steady demand for quality medicines, a rising vehicle base and strong housing construction keep widening the market for these companies. The main drivers are as follows. Pharma. Doctors prescribe trusted brands widely. Tyres. More vehicles on the road need more tyres. Pipes and adhesives. New homes need plumbing and bonding products. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Ipca Laboratories performed financially?
Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
How has CEAT performed financially?
Ans. Revenue rose from Rs 9,375 crore in FY22 to Rs 15,718 crore in FY26, a compound annual growth rate of 13.8%. Net profit grew from Rs 182 crore in FY23 to Rs 697 crore in FY26, which works out to a compound annual growth rate of 56.4%. The company has a return on equity of 11.5%, a debt to equity ratio of 0.82 and a market capitalisation of Rs 12,385 crore. The stock trades at a P/E of 24.0, above the industry P/E of 19.2. Looking ahead, the company is widening its premium and radial tyre range and growing its dealer network, which helps it capture the shift to better tyres. A balanced mix of original equipment and replacement sales supports steady demand.
How has Astral performed financially?
Ans. Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore. The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P/E of 66.5, above the industry P/E of 36.4. Looking ahead, the company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.
What risks should investors check before buying pharma, tyre and pipe stocks?
Ans. Investors should check a few risks before buying pharma, tyre and pipe stocks. Pricing pressure. Generic prices can change by market. Rubber and carbon black costs. Raw material prices can move margins. Housing cycles. Real estate and building demand can vary with rates and sentiment. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, tyre and pipe stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
